Patient baseline characteristics.

IA: Invasive Aspergillosis, GMI: Galactomannan Optical Density Index, BDG: β-D-glucan. aUnderlying disease, comorbidities, and microbiologic diagnostic tests were not mutually exclusive. bAdministration of corticosteroids (0.3 mg/kg/day of prednisone equivalent) for a minimum of 3 weeks prior to enrollment. cFour patients with proven IA had a positive culture for Aspergillus species: 3 from normally sterile sites and 1 from a sputum/bronchoalveolar lavage culture. dPatients with positive GM and BDG as tested at the institutions they were enrolled at are included in this Table. Some of them had negative GM and BDG when tested at the central laboratory for the purposes of this study. eOne patient had both sinusitis and lower tract respiratory involvement. fSix and 2 patients were treated with liposomal amphotericin B and amphotericin B deoxycholate, respectively. gOne patient was treated with fluconazole alone and the other patient received blinded treatment with a mould acting agent as part of a clinical trial. hPatients received more than one agent concomitantly: echinocandin and voriconazole (n = 2), echinocandin and amphotericin B deoxycholate (n = 1), and voriconazole and amphotericin B deoxycholate (n = 1). Patient baseline characteristics.